MASP2

Across TCGA pan-cancer cohorts, MASP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MASP2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MASP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MASP2 expression acts as an unfavorable survival marker.

PDAC, LUAD, and COAD are the cancer types where MASP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.327	0.725	.001	40	view →
LUAD	DFS	Median	II,III,IV	0.734	0.925	.001	33	view →
COAD	DFS	Median	All	0.695	1.000	.024	12	view →
CCRCC	DFS	Median	All	0.645	0.904	.032	7	view →
UCEC	DFS	Median	All	0.745	0.969	.009	4	view →
LSCC	OS	Tertile	All	0.915	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MASP2–PDAC (OS)

Open the PDAC breakdown →